{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T16:56:31Z","timestamp":1761843391680},"reference-count":82,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[1996,7,1]],"date-time":"1996-07-01T00:00:00Z","timestamp":836179200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[1996,7]]},"DOI":"10.1007\/bf01212877","type":"journal-article","created":{"date-parts":[[2005,2,25]],"date-time":"2005-02-25T19:10:06Z","timestamp":1109358606000},"page":"383-396","source":"Crossref","is-referenced-by-count":27,"title":["The future of antihormone therapy: innovations based on an established principle"],"prefix":"10.1007","volume":"122","author":[{"given":"Karsten","family":"Parczyk","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin R.","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"CR1","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/j.1749-6632.1995.tb31378.x","volume":"761","author":"E Angerer von","year":"1995","unstructured":"Angerer E von, Biberger C, Leichtl S (1995) Studies on heterocycle based pure antagonists. Ann NY Acad Sci 761:176?191","journal-title":"Ann NY Acad Sci"},{"key":"CR2","first-page":"7","volume":"43","author":"CC Boring","year":"1993","unstructured":"Boring CC, Squires TS, Tong T (1993) Cancer statistics. CA 43:7?26","journal-title":"CA"},{"key":"CR3","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1677\/erc.0.0020203","volume":"2","author":"AO Brinkmann","year":"1995","unstructured":"Brinkmann AO, Trapman J (1995) Mutant androgen receptors in endocrine-related cancer. Endocr Relat Cancer 2:203?214","journal-title":"Endocr Relat Cancer"},{"key":"CR4","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/pros.2990180304","volume":"18","author":"JR Brooks","year":"1991","unstructured":"Brooks JR, Berman C, Nguyen H, Prahalada S, Primka RL, Rasmusson GH, Slater EE (1991) Effect of castration, DES, flutamide, and the 5?-reductase inhibitor, MK-906, on the growth of the Dunning rat prostatic carcinoma, R-3327. Prostate 18:215?227","journal-title":"Prostate"},{"key":"CR5","first-page":"390","volume":"143","author":"M Colombel","year":"1993","unstructured":"Colombel M, Symmans F, Gil S, O'Toole KM, Chopin D, Benson M, Olsson CA, Korsmeyer S, Buttyan R (1993) Detection of the apoptosis-suppressing oncoprotein bcl-2 in hormone-refractory human prostate cancers. Am J Pathol 143:390?400","journal-title":"Am J Pathol"},{"key":"CR6","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1056\/NEJM198908173210702","volume":"321","author":"E Crawford","year":"1989","unstructured":"Crawford E, Eisenberger MA, McLeod, DG, Spaulding JT, Benson R, Dorr FA, Blumenstein BA, Davis MA, Goodman PJ (1989) A controlled trial of leuprolide with and without flutamide in prostatic carcinoma N Engl J Med 321:419?424","journal-title":"N Engl J Med"},{"key":"CR7","first-page":"5474","volume":"54","author":"Z Culig","year":"1994","unstructured":"Culig Z, Hobisch A, Cronauer MV, Radmayr C, Trapman J, Hittmair A, Bartsch G, Klocker H (1994) Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res 54:5474?5478","journal-title":"Cancer Res"},{"key":"CR8","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/BF00254431","volume":"15","author":"L D\u00e6hlin","year":"1987","unstructured":"D\u00e6hlin L, Bergh A, Damber JE (1987) Direct effects of oestradiol on growth and morphology of the Dunning R3327H prostatic carcinoma. Urol Res 15:169?172","journal-title":"Urol Res"},{"key":"CR9","doi-asserted-by":"crossref","first-page":"4037","DOI":"10.1073\/pnas.89.9.4037","volume":"89","author":"S Dauvois","year":"1992","unstructured":"Dauvois S, Danielian PS, White R, Parker MG (1992) Antiestrogen ICI 164, 384 reduces cellular estrogen receptor content by increasing its turnover Proc Natl Acad Sci USA 89:4037?4041","journal-title":"Proc Natl Acad Sci USA"},{"key":"CR10","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1242\/jcs.106.4.1377","volume":"106","author":"S Dauvois","year":"1993","unstructured":"Dauvois S, White R, Parker MG (1993) The antiestrogen ICI 182780 discrupts estrogen receptor nucleocytoplasmic shuttling. J Cell Sci 106:1377?1388","journal-title":"J Cell Sci"},{"key":"CR11","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0960-9776(94)90045-0","volume":"3","author":"DJ DeFriend","year":"1994","unstructured":"DeFriend DJ, Howell A (1994) Tamoxifen withdrawal responseschance observations or clinical clues to antioestrogen, resistance? Breast 3:199?201","journal-title":"Breast"},{"key":"CR12","doi-asserted-by":"crossref","first-page":"4421","DOI":"10.1073\/pnas.90.10.4421","volume":"90","author":"K Delabre","year":"1993","unstructured":"Delabre K, Guiochon-Mantel, A, Milgrom E (1993) In vivo evidence against the existence of antiprogestins disrupting receptor binding to DNA. Proc Natl Acad Sci USA 90:4421?4425","journal-title":"Proc Natl Acad Sci USA"},{"key":"CR13","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1677\/joe.0.1410335","volume":"141","author":"M Dukes","year":"1994","unstructured":"Dukes M, Chester R, Yarwood L, Wakeling AE (1994) Effects of a non-steroidal pure antioestrogen, ZM 189,154, on oestrogen target organs of the rat including bones. J Endocrinol 141:335?341","journal-title":"J Endocrinol"},{"key":"CR14","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/S0022-5347(17)35646-X","volume":"150","author":"A Dupont","year":"1993","unstructured":"Dupont A, Gomez JL, Cusan L, Koutsilieris M, Labrie F (1993) Response to flutamide withdrawal in advanced prostate cancer in progression under combination therapy. J Urol 150:908","journal-title":"J Urol"},{"key":"CR15","first-page":"85","volume-title":"Clinical endocrinology and metabolism vol 4","author":"CL Eaton","year":"1990","unstructured":"Eaton CL, Griffiths K (1990) The role of endocrine therapy in prostatic cancer. In: Shalet SM (ed). Clinical endocrinology and metabolism vol 4. Bailli\u00e8re Tindall, London, pp 85?96"},{"key":"CR16","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/pros.2990110408","volume":"11","author":"MF Etreby El","year":"1987","unstructured":"El Etreby MF, Habenicht UF, Louton T, Nishino Y, Schr\u00f6der G (1987) Effect of cyproterone acetate in comparison to flutamide and megestrol acetate on the ventral prostate, seminal vesicle, and adrenal glands of adult male rats. Prostate 11:361?375","journal-title":"Prostate"},{"key":"CR17","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1016\/0277-5379(87)90446-9","volume":"23","author":"A Forbes","year":"1987","unstructured":"Forbes A, Wilkinson ML, Iqbal MJ, Johnson PJ, Williams R (1987) Response to cyproterone acetate treatment in primary hepatocellular carcinoma is related to fall in free 5?-dihydrotestosterone. Eur J Cancer Clin Oncol 23:1659?1664","journal-title":"Eur J Cancer Clin Oncol"},{"key":"CR18","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1002\/1097-0142(19930201)71:3+<1039::AID-CNCR2820711423>3.0.CO;2-H","volume":"71","author":"J Geller","year":"1993","unstructured":"Geller J (1993) Basis for hormonal management of advanced prostate cancer. Cancer 71:1039?1045","journal-title":"Cancer"},{"key":"CR19","first-page":"4090","volume":"49","author":"MM Gottardis","year":"1989","unstructured":"Gottardis MM, Jiang SY, Jeng MH, Jordan VC (1989) Inhibition of tamoxifen-stimulated growth of an MCF-7 tumor variant in athymic by novel steroidal antiestrogens. Cancer Res 49:4090?4093","journal-title":"Cancer Res"},{"key":"CR20","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/0960-0760(92)90347-L","volume":"41","author":"H Gronemeyer","year":"1992","unstructured":"Gronemeyer H, Benhamou B, Berry MT, Gofflo D, Garcia T, Lerone T, Metzger D, Meyer ME, Tora L, Vergezac A, Chambon D (1992) Mechanism of antihormone action. J Steroid Biochem Mol Biol 41:217?221","journal-title":"J Steroid Biochem Mol Biol"},{"key":"CR21","first-page":"124","volume":"336","author":"HR Haak","year":"1990","unstructured":"Haak HR, Keizer RJW de, Hagennouw-Taal JCW, Seters AP van, Vielvoye GJ, Dulken H van (1990) Successful mifepristone treatment of recurrent, inoperable meningioma. Lancet 336:124?125","journal-title":"Lancet"},{"key":"CR22","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1007\/BF01215924","volume":"119","author":"DW Horn","year":"1993","unstructured":"Horn DW, Vollmer G, Deerberg F, Schneider MR (1993) The EnDA endometrial adenocarcinoma: an oestrogen-sensitive, metastasizing, in vivo tumor model of the rat. J Cancer Res Clin Oncol 119:450?456","journal-title":"J Cancer Res Clin Oncol"},{"key":"CR23","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1002\/ijc.2910580320","volume":"58","author":"DW Horn","year":"1994","unstructured":"Horn DW, Vollmer G, Angerer E von, Schneider MR (1994) Effect of the nonsteroidal antiestrogen ZK 119.010 on growth and metastasis of the EnDA endometrial carcinoma. Int J Cancer 58:426?429","journal-title":"Int J Cancer"},{"key":"CR24","first-page":"323","volume":"10","author":"G Horvath","year":"1990","unstructured":"Horvath G, Stendahl U, Kalling M, Fern\u00fco M, Himmelmann A, Hajba A (1990) Antiestrogenic treatment of advanced and recurrent carcinoma corpus uteri?a phase-II study of toremifene. Anticancer Res 10:323?326","journal-title":"Anticancer Res"},{"key":"CR25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1210\/edrv-13-1-1","volume":"13","author":"KB Horwitz","year":"1992","unstructured":"Horwitz KB (1992) The molecular biology of RU 486. Is there a role for antiprogestins in the treatment of breast cancer? Endocr Rev 13:1?17","journal-title":"Endocr Rev"},{"key":"CR26","first-page":"67","volume-title":"Clinical endocrinology and metabolism, vol 4","author":"A Howell","year":"1990","unstructured":"Howell A, Dodwell DJ, Anderson H (1990) New endocrine approaches to breast cancer. In: Shalet SM (ed). Clinical endocrinology and metabolism, vol 4. Bailli\u00e8re Tindall, London, pp 67?84"},{"key":"CR27","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(95)91156-1","volume":"345","author":"A Howell","year":"1995","unstructured":"Howell A, DeFriend D, Robertson J, Blamey R, Walton P (1995) Response to a specific antioestrogen (ICI 182780) in tamoxifenresistant breast cancer. Lancet 345:29?30","journal-title":"Lancet"},{"key":"CR28","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/0277-5379(91)90030-H","volume":"27","author":"TWA Huisman","year":"1991","unstructured":"Huisman TWA, Tanghe HLJ, Koper JW, Reubi JC, Foekens JA, Avezaat CJJ, Braakman R, Lamberts SWJ (1991) Progesterone, oestradiol, somatostatin and epidermal growth factor receptors on human meningiomas and their CT characteristics. Eur J Cancer 27:1453?1457","journal-title":"Eur J Cancer"},{"key":"CR29","doi-asserted-by":"crossref","first-page":"4658","DOI":"10.1073\/pnas.89.10.4658","volume":"89","author":"DM Ignar-Trowbridge","year":"1992","unstructured":"Ignar-Trowbridge DM, Nelson KG, Bidwell MC, Curtis SW, Washburn TF, McLachlan JA, Korach KS (1992) Coupling of dual signaling pathways: epidermal growth factor action involves the estrogen receptor. Proc. Natl Acad Sci USA 89:4658?4662","journal-title":"Proc. Natl Acad Sci USA"},{"key":"CR30","first-page":"266","volume":"63","author":"TJ Iveson","year":"1993","unstructured":"Iveson TJ, Smith IE, Ahern J, Smithers DA, Trunet PF, Dowsett M (1993) Phase I study of the oral nonsteroidal aromatase inhibitor CGS 20267 in postmenopausal patients with advanced breast cancer. Cancer Res 63:266?270","journal-title":"Cancer Res"},{"key":"CR31","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/j.1476-5381.1993.tb13840.x","volume":"110","author":"VC Jordan","year":"1993","unstructured":"Jordan VC (1993) A current view of tamoxifen for the treatment and prevention of breast cancer. Br J Pharmacol 110:507?517","journal-title":"Br J Pharmacol"},{"key":"CR32","first-page":"5312","volume":"49","author":"DT Kiang","year":"1989","unstructured":"Kiang DT, Kollander RE, Thomas T, Kennedy BJ (1989) Up-regulation of estrogen receptors by nonsteroidal antiestrogens in human breast cancer. Cancer Res 49:5312?5316","journal-title":"Cancer Res"},{"key":"CR33","first-page":"475","volume":"16","author":"F Labrie","year":"1993","unstructured":"Labrie F, Belanger A, Dupont A, Luu-The V, Simard J, Labrie C (1993) Science behind total androgen blockade: from gene to combination therapy. Clin Invest Med 16:475?492","journal-title":"Clin Invest Med"},{"key":"CR34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/jcp.1041640102","volume":"164","author":"M Li","year":"1995","unstructured":"Li M, Spitzer E, Zschiesche W, Binas B, Parczyk K, Grosse R (1995) Antiprogestins inhibit growth and stimulate differentiation in the normal mammary gland. J Cell Physiol 164:1?8","journal-title":"J Cell Physiol"},{"key":"CR35","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1002\/ijc.2910430424","volume":"43","author":"M Maasberg","year":"1989","unstructured":"Maasberg M, Rotsch M, Jaques G, Enderle-Schmidt U, Weehle R, Havemann K (1989) Androgen receptors, androgen-dependent proliferation, and 5?-reductase activity of small-cell lung cancer cell lines. Int J Cancer 43:685?691","journal-title":"Int J Cancer"},{"key":"CR36","unstructured":"Madjno R, Parczyk K, Michna H, Schneider MR (1995) The impact of tamoxifen and the pure antiestrogen ZM 182780 on the estrogen and progesterone receptor levels in rat mammary carcinoma and uterine tissue. In: 12th International Symposium of the Jouranl of Biochemistry and Molecular Biology, 21?24 May 1995, Berlin"},{"key":"CR37","doi-asserted-by":"crossref","first-page":"11945","DOI":"10.1016\/S0021-9258(17)32664-9","volume":"269","author":"DP McDonnell","year":"1994","unstructured":"McDonnell DP, Goldman ME (1994) RU486 exerts antiestrogenic activities through a novel progesterone receptor A form-mediated mechanism. J Biol Chem 269:11945?11949","journal-title":"J Biol Chem"},{"key":"CR38","doi-asserted-by":"crossref","first-page":"10563","DOI":"10.1073\/pnas.89.22.10563","volume":"89","author":"DP McDonnell","year":"1992","unstructured":"McDonnell DP, Vegeto E, O'Malley BW (1992) Identification of a negative regulatory function for steroid receptors. Proc Natl Acad Sci USA 89:10563?10567","journal-title":"Proc Natl Acad Sci USA"},{"key":"CR39","first-page":"6940","volume":"52","author":"TJ McDonnell","year":"1992","unstructured":"McDonnell TJ, Troncoso P, Brisbay SM, Logothetis C, Chung LWK, Hsieh JT, Tu SM, Campbell ML (1992) Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 52:6940?6944","journal-title":"Cancer Res"},{"key":"CR40","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/0022-4731(89)90126-X","volume":"34","author":"H Michna","year":"1989","unstructured":"Michna H, Schneider MR, Nishino Y, El Etreby MF (1989) The antitumor mechanism of progesterone antagonists is a receptor mediated antiproliferative effect by induction of terminal cell death. J Steroid Biochem 34:447?453","journal-title":"J Steroid Biochem"},{"key":"CR41","doi-asserted-by":"crossref","unstructured":"Michna H, Fritzemeier KH, Parczyk K, Nishino Y, Schneider MR (1996) Antiprogestin-progesterone interactions. In: Lippmann ME, Dickson RB (eds) Breast cancer: cellular and molecular biology","DOI":"10.1007\/978-1-4613-1259-8_10"},{"key":"CR42","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1002\/pros.2990160307","volume":"16","author":"BG Mobbs","year":"1990","unstructured":"Mobbs BG, Johnson IE, Liu Y (1990) Quantitation of cytosolic and nuclear estrogen and progesterone receptor in benign, untreated, and treated malignant human prostatic tissue by radioligand binding and enzyme-immunoassays. Prostate 16:235?244","journal-title":"Prostate"},{"key":"CR43","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/BF01811960","volume":"21","author":"HB Muss","year":"1992","unstructured":"Muss HB (1992) Endocrine therapy for advanced breast cancer: a review. Breast Cancer Res Treat 21:15?26","journal-title":"Breast Cancer Res Treat"},{"key":"CR44","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S0022-4731(83)80052-1","volume":"19","author":"F Neumann","year":"1983","unstructured":"Neumann F (1983) Pharmacological basis for clinical use of antiandrogens. J Steroid Biochem 19:391?402","journal-title":"J Steroid Biochem"},{"key":"CR45","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1677\/erc.0.0010005","volume":"1","author":"RI Nicholson","year":"1994","unstructured":"Nicholson RI, Francis AB, McClelland RA, Manning DL, Gee JMW (1994) Pure anti-oestrogens (ICI 164384 and ICI 182780) and breast cancer: is the attainment of complete oestrogen withdrawal worthwile? Endocr Relat Cancer 1:5?17","journal-title":"Endocr Relat Cancer"},{"key":"CR46","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/S0022-5347(01)67644-4","volume":"153","author":"PT Nieh","year":"1995","unstructured":"Nieh PT (1995) Withdrawal phenomenon with the antiandrogen casodex. J Urol 153:1070?1073","journal-title":"J Urol"},{"key":"CR47","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1007\/BF01236387","volume":"120","author":"Y Nishino","year":"1994","unstructured":"Nishino Y, Schneider MR, Michna H (1994) Enhancement of the antitumor efficacy of the antiprogestin, onapristone, by combination with the antiestrogen, ICI 164384. J Cancer Res Clin Oncol 120:298?302","journal-title":"J Cancer Res Clin Oncol"},{"key":"CR48","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1093\/jnci\/87.10.746","volume":"87","author":"CK Osborne","year":"1995","unstructured":"Osborne CK, Ester B, Coronado-Heinsohn, Susan G, Hilsenbeck, Bryant L, McCue, Wakeling AE, Richard A, McClelland, Manning DL, Nicholson RI (1995) Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer. J Natl Cancer Inst 87:746?750","journal-title":"J Natl Cancer Inst"},{"key":"CR49","unstructured":"Parczyk K, Madjno R, Angerer E von, Schneider MR (1995) Various pure antiestrogens downregulated the ER while partial agonists do not. In: 12th International Symposium of the Journal of Steroid Biochemistry and Molecular Biology, 21?24 May 1995, Berlin"},{"key":"CR50","unstructured":"Parczyk K, Michna H (1996) Androgen withdrawal reduces androgen receptor immunoreactivity in rat prostate carcinoma in contrast to androgen receptor antagonists. J Steroid Biochem Mol Biol"},{"key":"CR51","first-page":"663","volume-title":"Principles and practice of gynaecologic oncology","author":"R Park","year":"1992","unstructured":"Park R, Grigsby PW, Muss H, Norris HJ (1992) Corpus: epithelial tumors. In: Hoskins W, Perez C, Young R (eds) Principles and practice of gynaecologic oncology. Lippincott, Philadelphia, pp 663?693"},{"key":"CR52","first-page":"67P","volume":"89","author":"JS Patterson","year":"1981","unstructured":"Patterson JS (1981) Clinical aspects and development of anti-oestrogen therapy: a review of the endocrine effects of tamoxifen in animals and man. J Endocrinol 89:67P-75P","journal-title":"J Endocrinol"},{"key":"CR53","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1002\/pros.2990090405","volume":"9","author":"V Petrow","year":"1986","unstructured":"Petrow V (1986) The dihydrotestosterone (DHT) hypothesis of prostate cancer and its therapeutic implications. Prostate 9:343?361","journal-title":"Prostate"},{"key":"CR54","doi-asserted-by":"crossref","first-page":"3125","DOI":"10.1073\/pnas.88.8.3125","volume":"88","author":"TA Pham","year":"1991","unstructured":"Pham TA, Elliston JF, Nawaz Z, McDonnell DP, Tsai MJ, O'Malley BW (1991) Antiestrogen can establish nonproductive receptor complexes and alter chromatin structure at target enhances. Proc Natl Acad Sci USA 88:3125?3129","journal-title":"Proc Natl Acad Sci USA"},{"key":"CR55","first-page":"371","volume":"15","author":"D Raghaven","year":"1988","unstructured":"Raghaven D (1988) Non-hormone chemotherapy for prostate cancer: principles of treatment and application to the testing of new drugs. Semin Oncol 15:371?389","journal-title":"Semin Oncol"},{"key":"CR56","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1083\/jcb.124.1.1","volume":"124","author":"JC Reed","year":"1994","unstructured":"Reed JC (1994) Bcl-2 and the regulation of programmed cell death. J Cell Biol 124:1?6","journal-title":"J Cell Biol"},{"key":"CR57","first-page":"735","volume":"144","author":"JA Ruizeveld de Winter","year":"1994","unstructured":"Ruizeveld de Winter JA, Janssen PJ, Sleddens HM, Verleum-Mooijman MC, Trapman J, Brinkmann AO, Santerse AB, Schroder FH, van derKwast TH (1994) Androgen receptor status in localized and locally progressive hormone refractory human. Am J Pathol 144:735?46","journal-title":"Am J Pathol"},{"key":"CR58","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1210\/edrv-11-2-221","volume":"11","author":"RJ Santen","year":"1990","unstructured":"Santen RJ, Manni A, Harvey H, Redmond C (1990) Endocrine treatment of breast cancer in women. Endocr Rev 11:221?265","journal-title":"Endocr Rev"},{"key":"CR59","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1002\/j.1460-2075.1991.tb07713.x","volume":"10","author":"JF Savouret","year":"1991","unstructured":"Savouret JF, Bailly A, Misrahi M, Rauch C, Redeuilh G, Chauchereau A, Milgrom E (1991) Characterization of the hormone responsive element involved in the regulation of the progesterone receptor gene. EMBO J 10:1875?1883","journal-title":"EMBO J"},{"key":"CR60","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1200\/JCO.1993.11.8.1566","volume":"11","author":"HI Scher","year":"1993","unstructured":"Scher HI, Kelly WK (1993) The flutamide withdrawal syndrome: Its impact on clinical trials in hormone-refractory prostatic cancer. J Clin Oncol 11:1566?1572","journal-title":"J Clin Oncol"},{"key":"CR61","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/0960-0760(93)90270-7","volume":"44","author":"K Schieweck","year":"1993","unstructured":"Schieweck K, Bhatnagar AS, Batzl CH, Lang M (1993) Anti-tumor and endocrine effects of non-steroidal aromatase inhibitors on estrogen-dependent rat mammary tumors. J Steroid Biochem Mol Biol 44:633?636","journal-title":"J Steroid Biochem Mol Biol"},{"key":"CR62","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1002\/ardp.19933261003","volume":"326","author":"MR Schneider","year":"1993","unstructured":"Schneider MR (1993) Antihormone: Von der Entdeckung der Steroidhormone zu spezifischen Krebstherapeutika. Arch Pharm (Weinheim) 326:769?784","journal-title":"Arch Pharm (Weinheim)"},{"key":"CR63","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/0277-5379(89)90206-X","volume":"25","author":"MR Schneider","year":"1989","unstructured":"Schneider MR, Michna H, Nishino Y, El Etreby MF (1989) Antitumor activity of the progesterone antagonists ZK 98299 and RU486 in the hormone-dependent MXT mammary tumor model of the mouse and the DMBA- and MNU-induced mammary tumor model of the rat. Eur J Cancer Clin Oncol 25:691?701","journal-title":"Eur J Cancer Clin Oncol"},{"key":"CR64","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/BF01612671","volume":"116","author":"MR Schneider","year":"1990","unstructured":"Schneider MR, Humm A, Graf AH (1990a) The tumor-inhibiting effect of diethylstilbestrol and its diphosphate on the Nb?H and Nb?R prostatic carcinomas of the rat. J Cancer Res Clin Oncol 116:159?167","journal-title":"J Cancer Res Clin Oncol"},{"key":"CR65","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/0960-0760(90)90420-P","volume":"37","author":"MR Schneider","year":"1990","unstructured":"Schneider MR, Michna H, Nishino Y, El Etreby MF (1990b) Antitumor activity and mechanism of action of different antiprogestins in experimental breast cancer models. J Steroid Biochem Mol Biol 37:783?787","journal-title":"J Steroid Biochem Mol Biol"},{"key":"CR66","first-page":"99","volume-title":"Attualita endocrine in oncologia ginecologica e in medicina del riproduzione","author":"MR Schneider","year":"1991","unstructured":"Schneider MR, Michna H, Nishino Y, Henderson D (1991) Antitumor activity and mechanism of action of progesterone antagonists in experimental breast cancer. In: Masobrio M, Menato G, Cassoni P, Simonetta M (eds) Attualita endocrine in oncologia ginecologica e in medicina del riproduzione. Monduzzi, Bologna, pp 99?105"},{"key":"CR67","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/BF01410132","volume":"118","author":"MR Schneider","year":"1992","unstructured":"Schneider MR, Michna H, Habenicht UF, Nishino Y, Grill HJ, Pollow K (1992) The tumor-inhibiting potential of the progesterone antagonist onapristone in the human mammary carcinoma T61 in nude mice. J Cancer Res Clin Oncol 118:187?189","journal-title":"J Cancer Res Clin Oncol"},{"key":"CR68","doi-asserted-by":"crossref","first-page":"6120","DOI":"10.1073\/pnas.90.13.6120","volume":"90","author":"CL Smith","year":"1993","unstructured":"Smith CL, Conneely OM, O'Malley BW (1993) Modulation of the ligand-independent activation of the human estrogen receptor by hormone and antihormone. Proc Natl Acad Sci USA 90:6120?6124","journal-title":"Proc Natl Acad Sci USA"},{"key":"CR69","first-page":"322","volume-title":"Cancer chemotherapy","author":"GD Steinberg","year":"1993","unstructured":"Steinberg GD, Isaacs JT (1993) Pharmacological approaches to the management of metastatic prostatic cancer. In: Hickman JA, Tritton TR (eds) Cancer chemotherapy. Blackwell, London, pp 322?343"},{"key":"CR70","first-page":"15","volume":"12","author":"JF Steiner","year":"1993","unstructured":"Steiner JF (1993) Finasteride: a 5?-reductase inhibitor. Clin Pharm 12:15?23","journal-title":"Clin Pharm"},{"key":"CR71","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1056\/NEJM199505253322101","volume":"332","author":"ML Taplin","year":"1995","unstructured":"Taplin ML, Bubley GJ, Shuster TD, Frantz ME, Spooner AE, Ogata GK, Keer HN, Balk SP (1995) Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med 332:1393?1398","journal-title":"N Engl J Med"},{"key":"CR72","doi-asserted-by":"crossref","first-page":"11333","DOI":"10.1073\/pnas.91.24.11333","volume":"91","author":"M Truss","year":"1994","unstructured":"Truss M, Bartsch J, Beato M (1994) Antiprogestins prevent progesterone receptor binding to hormone responsive elements in vivo Proc Natl Acad Sci USA 91:11333?11337","journal-title":"Proc Natl Acad Sci USA"},{"key":"CR73","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1358\/dof.1990.015.03.115229","volume":"15","author":"H Tucker","year":"1990","unstructured":"Tucker H (1990) Non-steroidal anti-androgens in the treatment of prostate cancer. Drug Future 15:255?265","journal-title":"Drug Future"},{"key":"CR74","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/0960-0760(94)90144-9","volume":"48","author":"P Velde Van de","year":"1994","unstructured":"Van de Velde P, Nique F, Bouchoux F, Br\u00e9maud J, Hameau M-C, Lucas D, Moratille C, Viet S, Philibert D, Teutsch G (1994) RU 58 668, a new pure antiestrogen inducing a regression of human mammary carcinoma implanted in nude mice. J Steroid Biochem Mol Biol 48:187?196","journal-title":"J Steroid Biochem Mol Biol"},{"key":"CR75","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/ng0495-401","volume":"9","author":"T Visakorpi","year":"1995","unstructured":"Visakorpi T, Hyytinen E, Koivisto P, Tanner M, Kein\u00e4nen R, Palmberg C, Palotie A, Tammela T, Isola J, Kallioniemi OP (1995) In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet 9:401?406","journal-title":"Nat Genet"},{"key":"CR76","doi-asserted-by":"crossref","unstructured":"Vollmer G, Schneider MR (1996) The rat endometrial adenocarcinoma cell line Ruca-I: a novel hormone-responsive in vivo\/in vitro tumor model. J Steroid Biochem Mol Biol","DOI":"10.1016\/0960-0760(96)00012-X"},{"key":"CR77","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/pros.2990210514","volume":"4","author":"HJ Voogt de","year":"1992","unstructured":"Voogt HJ de (1992) The position of cyproterone acetate (CPA), a steroidal anti-androgen, in the treatment of prostate cancer. Prostate 4:91?95","journal-title":"Prostate"},{"key":"CR78","first-page":"43","volume-title":"Anti-oestrogens in oncology. Past, present and prospects","author":"AE Wakeling","year":"1985","unstructured":"Wakeling AE (1985) Chemical structure and pharmacology of antioestrogens. History, current trends and future prospects. In: Pannuti F (ed) Anti-oestrogens in oncology. Past, present and prospects. Excerpta Medica, Amsterdam Geneva. Hong Kong, pp 43?53"},{"key":"CR79","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/0022-4731(89)90081-2","volume":"34","author":"AE Wakeling","year":"1989","unstructured":"Wakeling AE (1989) Comparative studies on the effects of steroidal and nonsteroidal oestrogen antagonists on the proliferation of human breast cancer cells. J Steroid Biochem 34:183?188","journal-title":"J Steroid Biochem"},{"key":"CR80","doi-asserted-by":"crossref","first-page":"R7","DOI":"10.1677\/joe.0.112R007","volume":"112","author":"AE Wakeling","year":"1987","unstructured":"Wakeling AE, Bowler J (1987) Steroidal pure antiestrogens. J Endocrinol 112:R7-R10","journal-title":"J Endocrinol"},{"key":"CR81","first-page":"3867","volume":"51","author":"AG Wakeling","year":"1991","unstructured":"Wakeling AG, Dukes M, Bowler J (1991) A potent specific pure antiestrogen with clinical potential. Cancer Res 51:3867?3873","journal-title":"Cancer Res"},{"key":"CR82","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/978-88-470-2186-0_11","volume":"124","author":"GF Weinbauer","year":"1992","unstructured":"Weinbauer GF, Nieschlag E (1992) LH-RH antagonists: state of the art and future perspectives. Recent Results Cancer Res 124:113?136","journal-title":"Recent Results Cancer Res"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF01212877.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF01212877\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF01212877","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,5]],"date-time":"2021-07-05T19:18:11Z","timestamp":1625512691000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF01212877"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1996,7]]},"references-count":82,"journal-issue":{"issue":"7","published-print":{"date-parts":[[1996,7]]}},"alternative-id":["BF01212877"],"URL":"https:\/\/doi.org\/10.1007\/bf01212877","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[1996,7]]}}}